Retinal Disease Pharmaceutical Sales Will Reach $12.5bn In 2019, A New Visiongain Study Predicts

LONDON - March 18, 2015 - PRLog -- LONDON, UK, 23^rd of February 2015: A new report by visiongain (http://www.visiongain.com/) forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $12.5bn in 2019. That revenue forecast and others appear in Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 (https://www.visiongain.com/Report/1403/Macular-Degeneration-%28AMD%29-and-Other-Retinal-Diseases-World-Drug-Industry-and-Market-2015-2025), published in February 2015.

The purpose of that investigation is to give forecasting that planners, influencers and leaders need. Visiongain is a business information publisher and consultancy in London, UK. It produces analysis to help organisations understand industries, markets and their potentials.

Those analyses reveal prospects for companies developing, producing and marketing drugs for treating wet age-related macular degeneration, dry AMD and diabetic retinopathy. That work also covers geographic atrophy (GA), diabetic macular oedema/edema (DME), proliferative and non-proliferative diabetic retinopathy (PDR and NPDR) and retinal vein occlusion (RVO). It assesses biological drugs (biologics) – especially monoclonal antibodies (mAbs) – and other medicines, including emerging and expected treatments.

Visiongain predicts the overall retinal disease drugs market (https://www.visiongain.com/Pharma/47/Reports) will multiply in size for revenues from 2015 to 2025. That retinal treatments market will expand as unmet patients’ needs are fulfilled and therapies improved upon. Although there are treatment options for wet AMD, pharmaceutical companies will seek to improve the standard of care and expand options by adding new indications for previously approved drugs. Dry AMD, which currently has no approved treatments, has promising candidates in development. Visiongain believes the overall market will be stimulated by aging populations and rising prevalence of diabetes.

Alyscia Curtis, a pharmaceutical industry analyst in visiongain, said: “The AMD and other retinal diseases market has the potential to expand substantially in the next ten years. Though that market is driven by the success of agents targeting vascular endothelial growth factor (VEGF) in the treatment of neovascular (‘exudative’ or ‘wet’) AMD, in diabetic macular oedema (DME) and other indications, such as macular oedema secondary to retinal vein occlusion (RVO), dAMD remains an untapped area of treatment. However there are promising R&D pipeline candidates.

“The patient population for retinal diseases is probably underestimated owing to low diagnosis rates, particularly for dAMD. Ageing populations and rising incidence of diabetes will continue to expand the patient population throughout the forecast period, further contributing to growth of the market. Pushback from healthcare agencies against high prices may restrain growth in the next 10 years. Focusing on expanding the indications for drugs has proved a crucial aspect to success for current treatments such Lucentis and Eylea. Although the AMD and other retinal diseases market was worth just over $6500m in 2013, a large portion of which were revenues for Lucentis and Eylea, visiongain predicts the market will grow to over $12,400m in 2019.”

That updated report shows revenue forecasts to 2025 at overall world market, disease submarket, product (brand) and national level. First it gives revenue predictions to 2025 for four therapeutic submarkets at world level:

Wet age-related macular degeneration (wAMD)
Dry AMD (dAMD)
Diabetic retinopathy (DR)
Other retinal diseases (grouped forecast).

That study then predicts revenues of five prominent drugs to 2025: Lucentis, Eylea, Avastin, Visudyne and Jetrea.

Research, data and analyses cover activities of Roche, Novartis, Bayer, Regeneron, Allergan, Valeant and other developers, manufacturers and marketers of ophthalmic pharmaceuticals. Analyses cover leaders and other organisations for retinal medicines.

That new study also discusses R&D and commercial news, shows two research interviews and predicts revenues to 2025 in 11 leading national markets. The work analyses the United States (US), Western Europe (Italy, Spain, Germany, the UK and France), Japan and BRIC countries (Brazil, Russia, India and China).

Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 adds to visiongain’s analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.

For sample pages and further information concerning the visiongain report Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 please visit :https://www.visiongain.com/Report/1403/Macular-Degeneration-%28AMD%29-and-Other-Retinal-Diseases-World-Drug-Industry-and-Market-2015-2025

For an executive summary or any other information about the Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 report, please contact: sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.